Short-Term Versus Conventional Glucocorticoid Therapy in Acute Exacerbations of COPD

Michele Reed, PharmD, RPh
Published Online: Tuesday, August 6, 2013
Follow Pharmacy_Times:
A recent study evaluated whether a short-term 5-day systemic glucocorticoid treatment in patients with chronic obstructive pulmonary disease (COPD) exacerbation is noninferior to a conventional 14-day treatment.2 This randomized, multicenter, placebo-controlled, double-blind trial was conducted from March 2006 through February 2011 in 5 Swiss teaching hospitals and studied patients (n = 314) presenting to the emergency department with acute COPD exacerbation and past or present smokers (≥20 pack-years) without a history of asthma. Patients were randomized to receive prednisone 40 mg daily for either 5 or 14 days. The primary outcome was time to next exacerbation within 180 days, and the predefined noninferiority criterion was an absolute increase in exacerbations of, at most, 15%, translating to a critical hazard ratio of 1.515, for a reference event rate of 50%.

Results showed that noninferiority criteria were met. Hazard ratios for the short-term versus conventional treatment group were 0.95 (90% CI, 0.70-1.29; P = .006 for noninferiority) in the intention-to-treat analysis and 0.93 (90% CI, 0.68 -1.26; P = .005 for noninferiority) in the per protocol analysis. In the short-term (5-day) treatment group, 56 patients (35.9%) reached the primary end point compared with 57 (36.8%) in the conventional (14-day) treatment group. The median time to event for re-exacerbation was 43.5 days (interquartile range [IQR], 13 to 118) in the short-term group and 29 days (IQR, 16 to 85) in the conventional group. The authors concluded that this study supports the use of a 5-day glucocorticoid treatment in acute exacerbations of COPD due to noninferiority to a conventional treatment course and reduction in glucocorticoid exposure.


Dr. Reed is a freelance writer in Fairless Hills, Pennsylvania.

References
  1. Marcus CL, Moore RH, Rosen CL, et al. A randomized trial of adenotonsillectomy for childhood sleep apnea. N Engl J Med. 2013;368(25):2366-2376.
  2. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223-2231.
  3. Buchs NC, Konrad-Mugnier B, Jannot AS, et al. Assessment of recurrence and complications following uncomplicated diverticulitis. Br J Surg. 2013;100(7):976-979.
 


Related Articles
Vitamin D supplements can reduce the severity and duration of chronic obstructive pulmonary disease flare-ups by more than 40%.
In a study of patients with comorbid COPD and metabolic syndrome, elevated triglyceride levels were associated with increased mortality rates.
The FDA is reviewing a regulatory application to add an asthma indication to Boehringer Ingelheim’s chronic obstructive pulmonary disease treatment, tiotropium bromide.
AstraZeneca today announced that it has completed the strategic transaction to transfer the rights to Almirall’s respiratory franchise to the company.
Latest Issues
$auto_registration$